CTOs on the Move

Celsis International Plc

www.celsis.com

 
Celsis International plc is a world leading provider of innovative life science products and laboratory services to the pharmaceutical, biopharmaceutical, and consumer products industries through its three business areas, rapid detection, analytical and
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.celsis.com
  • 600 W Chicago Ave
    Chicago, IL USA 60654
  • Phone: 312.476.1200

Executives

Name Title Contact Details

Similar Companies

Seattle Biomedical Research Institute

Seattle Biomedical Research Institute is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ImmunityBio

ImmunityBio is a vertically-integrated, clinical-stage biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The company`s range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. We are applying our science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases.

Lamination Technologies Inc

Lamination Technologies Inc is a Freeport, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pharmaessentia

PharmaEssentia Corporation is a rapidly growing biopharmaceutical innovator. We are leveraging deep expertise and proven scientific principles to deliver effective new biologics for challenging diseases in the areas of hematology and oncology, with one product approved in The United States and a diversifying pipeline. We believe in the potential to improve both health and quality of life for patients with limited options today through the combination of rigorous research and innovative thinking.

Autolus

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.